ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

Sarepta Therapeutics Stock Performance Shares of NASDAQ SRPT opened at $133.34 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The stock has a ...

Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our P/B Growth Investor model based on the published ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical ...